Page 4 - Nasdaq Immx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq immx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Immx Today - Breaking & Trending Today

Immix Biopharma Announces Positive NXC-201 Clinical Results

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8). ....

Los Angeles , United States , Grand View , Suzanne Messere , Polina Stepensky , Exchange Commission , International Myeloma Working Group , Nexcella Inc , Immix Biopharma Inc , View Research , American Society Of Gene , Annual Meeting , American Society , Cell Therapy , Hadassah Medical Organization , Bone Marrow Transplantation , Overall Response Rate , Clinical Trial , Efficacious Novel Modality , Light Chain Amyloidosis , Friday May , Late Breaking Abstracts , Uniform Response , Immix Biopharma , Tissue Specific Therapeutics , Rare Pediatric Disease Designation ,

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 86.8% in April

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Rating) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 221,300 shares, a growth of 86.8% from the April 15th total of 118,500 shares. Based on an average daily trading volume, of 201,700 shares, the days-to-cover ratio […] ....

United States , Roth Mkm , Lynwood Capital Management Inc , Immix Biopharma Company Profile , Renaissance Technologies , Immix Biopharma Inc , Topco Ltd , Virtu Financial , Immix Biopharma , Get Rating , Montreal Can , Capital Management , Immix Biopharma Daily , Nasdaq Immx ,

Nexcella, an Immix Biopharma subsidiary, Announces Positive

Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic. ....

United States , France General , Ilya Rachman , Suzanne Messere , Gabriel Morris , Polina Stepensky , Beigene Novarti , European Society For Blood , Immix Biopharma Inc , International Myeloma Working Group , Clinical Cancer Research , Hadassah Medical Center , Exchange Commission , View Research , Nexcella Inc , Multiple Myeloma , Grand View , Announces Positive , Overall Response Rate , Annual Meeting , Immix Biopharma , European Society , Marrow Transplantation , Hadassah Medical Organization , Bone Marrow Transplantation , Executive Chairman ,

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Rating) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 146,500 shares, an increase of 24.3% from the February 28th total of 117,900 shares. Approximately 2.5% of the shares of the stock are short sold. Based on […] ....

United States , Roth Mkm , Renaissance Technologies , Virtu Financial , Lynwood Capital Management Inc , Immix Biopharma Inc , Topco Ltd , Immix Biopharma , Get Rating , Montreal Can , Capital Management , Immix Biopharma Daily , Nasdaq Immx ,

Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Grows By 24.3%

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Rating) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 146,500 shares, a growth of 24.3% from the February 28th total of 117,900 shares. Based on an average daily volume of 182,200 shares, the days-to-cover ratio is […] ....

United States , Roth Mkm , Renaissance Technologies , Lynwood Capital Management Inc , Immix Biopharma Inc , Virtu Financial , Topco Ltd , Immix Biopharma , Get Rating , Montreal Can , Lynwood Capital Management , Immix Biopharma Daily , Nasdaq Immx ,